CD270/HVEM/TNFRSF14
Alpha Lifetech can provide CD270/HVEM/TNFRSF14 corresponding products, help each customer's research and development.
01
Introduction To CD270/HVEM/TNFRSF14
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD270/HVEM/TNFRSF14 protein is a common target in medicine.
HVEM, also known as TNFRSF14, CD270, is the only discovered ligand of BTLA and is one of the members of the tumor necrosis factor receptor superfamily. HVEM, a member of the TNF receptor family, is a transmembrane protein that structurally contains multiple extracellular cysteine-rich domains (CRD).HVEM is widely expressed in human immune cells, such as dendritic cells, initial T cells and B cells, NK cells, monocytes, and neutrophils. HVEM is also expressed on the surface of various tumor cells, including non-small cell lung cancer, melanoma, colorectal cancer, and lymphoma, and plays an important biological role in T cell proliferation, tumor immunity, transplantation immunity, inflammatory response, and autoimmune diseases.
Function of Target CD270/HVEM/TNFRSF14
HVEM can bind to different ligands to produce opposite effects. HVEM binding to BTLA produces immunosuppressive effects and negatively regulates the activation and proliferation of lymphocytes. However, binding to LIGHT or LT-α can stimulate the proliferation and activation of T cells and B cells, which has the effect of inducing an inflammatory response and providing a second stimulatory signal for T cell activation. Signaling by CD270 can activate signaling pathways such as NF-κB and AKT, thereby promoting cell survival and proliferation. In the tumor microenvironment, CD270 activity may be inhibited or overactivated, thereby affecting the immune evasion and immune surveillance of tumor cells.
Gene Pathway of Target CD270/HVEM/TNFRSF14
When CD270 binds with ligands such as LIGHT, LT, and co- α, it can recruit TNFR-related factors (TRAF) and activate the NF- κ B signaling pathway, thus promoting cell survival, and proliferation and playing a role in the inflammatory response. Signaling of CD270 may also be related to the PI3K / AKT signaling pathway, associated with cell survival rate, proliferation rate, and metabolic rate. CD270 exhibits two aspects of properties in immune regulation. HVEM binding to BTLA produces immunosuppressive effects and negatively regulates the activation and proliferation of lymphocytes. However, binding to LIGHT or LT- α can stimulate the proliferation and activation of T cells and B cells, which has the effect of inducing an inflammatory response and providing a second stimulatory signal for T cell activation.
Fig 1: HVEM Gene Pathway. (Reference source: Shui JW, Kronenberg M. HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes. Gut Microbes. 2013 Mar-Apr;4(2):146-51.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD270/HVEM/TNFRSF14 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD270/HVEM/TNFRSF14 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD270/HVEM/TNFRSF14 protein products are also essential. Alpha Lifetech can provide CD270/HVEM/TNFRSF14 corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide efficient and accurate EC50 / IC50, helping customer companies to screen compounds efficiently and accurately. At the same time, Alpha Lifetech also provides some services such as recombinant antibody production and recombinant antibody purification, to conduct in vitro affinity screening to ensure the maturity of recombinant antibody affinity and help customers in antibody drug discovery, and subsequent various experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64676 | 50ug,100ug,500ug | |
| ALP64660 | 50ug,100ug,500ug | |
| ALP64639 | 50ug,100ug,500ug | |
| ALP64553 | 50ug,100ug,500ug | |
Reference
[1] Shui JW, Kronenberg M. HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes. Gut Microbes. 2013 Mar-Apr;4(2):146-51.
[2] Diethelm P, Schmitz I, Iten I, Kisielow J, Matsushita M, Kopf M. LCMV-induced downregulation of HVEM on antiviral T cells is critical for an efficient effector response. Eur J Immunol. 2022 Jun;52(6):924-935.
[3] Shui JW, Kronenberg M. HVEM is a TNF Receptor with Multiple Regulatory Roles in the Mucosal Immune System. Immune Netw. 2014 Apr;14(2):67-72.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102